Instylla

Instylla is focused on developing next-generation liquid embolics for interventional radiology.

[Instylla @instylla]

Embrace the Case.
70F, acetabular bone met from RCC, 5.3 cm. Preoperative embolization before hip replacement. 3 vessels, single session. Surgical intervention enabled.

https://t.co/wOgBIBWNx7

#EmbraceHES #InterventionalOncology #IR

[Instylla @instylla]

Don't miss the Virtual Liquid & Conformable Embolic Summit tomorrow!

@thegestgroup has assembled an excellent lineup of faculty & topics across both sessions.

Still time to register: https://t.co/HObEuILL5y

#liquidembolics #interventionalradiology

[Instylla @instylla]

Some of our team made a stop at Times Square during #GEST2026 to see @Nasdaq mark the commercial launch of Embrace® HES. Not a bad way to celebrate our first year of commercialization.

[Instylla @instylla]

As #GEST2026 comes to a close, thank you to everyone who connected with us throughout the week. Special thanks to the GEST Group for an outstanding meeting.
#InterventionalRadiology #EmbraceHES #Embolization

[Instylla @instylla]

Attending #GEST2026? Don't miss the Hands-on Workshop: Particles, Liquids, and Conformables. Friday, May 15 | 8:00 AM | Lenox Ballroom.

Our team will be there, come see Embrace® HES on the flow model.

#InterventionalRadiology #EmbraceHES

[Instylla @instylla]

We're headed to #GEST2026 in New York City! Visit us at Booth #206 to learn more about Embrace® HES, the first and only FDA-approved liquid embolic for hypervascular tumor embolization supported by a prospective, randomized clinical trial.
#InterventionalRadiology #EmbraceHES

[Instylla @instylla]

SIR 2026 is almost here, and we could not be more excited. Hear from Instylla CEO, Sean Boyle on what we are looking forward to in Toronto. #SIR26TOR #EmbraceHES #Instylla #InterventionalRadiology

[Instylla @instylla]

We're heading to #SIR26TOR in Toronto! Visit us at Booth #1404 to learn about Embrace™ HES, the first and only FDA-approved liquid embolic for hypervascular tumor embolization, backed by a prospective, randomized clinical trial.

[Instylla @instylla]

Thank you to everyone who connected with us and shared meaningful conversations throughout #SIOSavannah. Special thanks to the @SIO_Central for hosting a great meeting.

[Instylla @instylla]

One of the highlights of #SIOSavannah has been hosting #IOEssentials participants at our booth. Huge thanks to @SIO_Central for creating such a great program.

[Instylla @instylla]

We’re on site for #SIOSavannah! The exhibit hall is open so come see us at Booth #313 to connect with our team and learn more about Embrace™ HES.

[Instylla @instylla]

We’re headed to #SIOSavannah!

Visit us at Booth #313 to learn more about Embrace™ HES, the first and only FDA-approved liquid embolic for hypervascular tumor embolization supported by a prospective, randomized clinical trial.

#InterventionalOncology #IR #Embolization

[Instylla @instylla]

We’re pleased to share that Dr. Ripal Gandhi has completed the first commercial procedure using the Embrace™ Hydrogel Embolic System, marking an important milestone following FDA Premarket Approval in August 2025. https://t.co/vRG9fsyjLh

[Instylla @instylla]

Thanks for visiting #Instylla at #CIO2025. We enjoyed connecting and discussing Embrace™ HES!
#ConfidenceinEveryCast #InterventionalOncology #Embolization #medicalinnovation #interventionalradiology #EmbraceHES

[Instylla @instylla]

A Time to Embrace—the future of liquid embolics is here.
Stop by Booth #103 to see Embrace™ HES, the first FDA-approved liquid embolic for hypervascular tumors, proven in a prospective randomized trial.
#CIO2025 #InterventionalOncology #IR #Embolization #EmbraceHES

[Instylla @instylla]

🎯 10 days to #CIO2025!
Join us in Miami at Booth #103 to see Embrace™ HES—the first FDA-approved liquid embolic for hypervascular tumors, backed by a prospective randomized trial.
#InterventionalOncology #IR #Embolization #EmbraceHES

[Instylla @instylla]

Join us on Saturday, Oct 18, at the Shelborne in Miami Beach @ 7:30 pm ET for dinner and a presentation event with Dr. David Tahour and Dr. Edgar St. Amour. Learn about the future of liquid embolics, the Embrace HES.
Reserve your seat here.
https://t.co/Roo78slqlK

[Instylla @instylla]

@instylla announces PMA approval for Embrace™ Hydrogel Embolic System, a novel liquid embolic. A milestone for embolization & IO.
#PMA #MedTech #IO #Embolization #IR https://t.co/thaqSMJ2d9

[Instylla @instylla]

Instylla Welcomes #MedTech Leader, Sean Boyle, as Chief Executive Officer! #interventionalradiology #leadership #embracehes https://t.co/M44KsZaSix

[Instylla @instylla]

Thanks for visiting #Instylla at #GEST2025. It was exciting to discuss our resorbable embolics, Embrace HES and the Tembo Embolic System.

#MedicalInnovation in #interventionalradiology, #interventionaloncology, #Embolization